WO2018004309A1 - 이중가닥 핵산 신호 프로브 및 이를 이용한 표적분자의 검출방법 - Google Patents
이중가닥 핵산 신호 프로브 및 이를 이용한 표적분자의 검출방법 Download PDFInfo
- Publication number
- WO2018004309A1 WO2018004309A1 PCT/KR2017/006987 KR2017006987W WO2018004309A1 WO 2018004309 A1 WO2018004309 A1 WO 2018004309A1 KR 2017006987 W KR2017006987 W KR 2017006987W WO 2018004309 A1 WO2018004309 A1 WO 2018004309A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signal probe
- signal
- region
- probe
- nucleic acid
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims abstract description 434
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 172
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 159
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 85
- 238000001514 detection method Methods 0.000 claims abstract description 95
- 230000027455 binding Effects 0.000 claims description 92
- 230000009870 specific binding Effects 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 239000000463 material Substances 0.000 claims description 59
- 230000011664 signaling Effects 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 46
- 108091023037 Aptamer Proteins 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 23
- 235000020958 biotin Nutrition 0.000 claims description 23
- 239000011616 biotin Substances 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 23
- 239000000020 Nitrocellulose Substances 0.000 claims description 21
- 108010090804 Streptavidin Proteins 0.000 claims description 21
- -1 antibody Proteins 0.000 claims description 21
- 229920001220 nitrocellulos Polymers 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 16
- 239000006249 magnetic particle Substances 0.000 claims description 12
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 150000001615 biotins Chemical group 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 5
- 230000009871 nonspecific binding Effects 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 9
- 238000010438 heat treatment Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 67
- 238000006243 chemical reaction Methods 0.000 description 49
- 108020004414 DNA Proteins 0.000 description 32
- 238000005516 engineering process Methods 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000011324 bead Substances 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 229920001213 Polysorbate 20 Polymers 0.000 description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 102000003960 Ligases Human genes 0.000 description 12
- 108090000364 Ligases Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 12
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 11
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 11
- 238000002331 protein detection Methods 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000002860 competitive effect Effects 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 238000003306 harvesting Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 6
- 239000011654 magnesium acetate Substances 0.000 description 6
- 235000011285 magnesium acetate Nutrition 0.000 description 6
- 229940069446 magnesium acetate Drugs 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 235000011056 potassium acetate Nutrition 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 5
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 5
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 5
- 102100033461 Interleukin-17A Human genes 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 5
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010016952 Food poisoning Diseases 0.000 description 4
- 208000019331 Foodborne disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000005001 aminoaryl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 3
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 3
- 101710112185 Phototropin-1 Proteins 0.000 description 3
- 108700028909 Serum Amyloid A Proteins 0.000 description 3
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000538 analytical sample Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000007169 ligase reaction Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000593245 Bionia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108091008103 RNA aptamers Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- 229960004469 methoxsalen Drugs 0.000 description 2
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011897 real-time detection Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229940027041 8-mop Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101000602237 Homo sapiens Neuroblastoma suppressor of tumorigenicity 1 Proteins 0.000 description 1
- 101001113490 Homo sapiens Poly(A)-specific ribonuclease PARN Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000186983 Streptomyces avidinii Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QPEJOQWVBDJCKB-NNFSRNKVSA-N ac1l8w4m Chemical compound C1([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](C3=CC=4OCOC=4C=C32)NC2=CC=C(C=C2)N=CC=2C3=CC=CC=C3N=C3C4=CC5=C(C(N4CC3=2)=O)COC(=O)[C@]5(O)CC)=CC(OC)=C(O)C(OC)=C1 QPEJOQWVBDJCKB-NNFSRNKVSA-N 0.000 description 1
- 239000007825 activation reagent Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052595 hematite Inorganic materials 0.000 description 1
- 239000011019 hematite Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000010842 industrial wastewater Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 150000002671 lyxoses Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Chemical group 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108010081020 traptavidin Proteins 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
Definitions
- the signal generating region Is a double-stranded nucleic acid that is complementarily crosslinked (ie covalently) with each other, wherein the double-stranded nucleic acid is labeled with the same signaling agent or two or more regions (wherein the "region” is optionally Is characterized by the presence of a "segment (segment)" in order to clearly distinguish it from other parts of the same or similar terms.
- Single-stranded nucleic acid as a specific binding region with a target molecule is a nuclease or a thermally stable PNA (Peptide Nucleic Acid) as long as it has a specific binding ability with not only single-stranded DNA or single-stranded RNA but also a nucleic acid such as mRNA, which is its target molecule.
- PNA Peptide Nucleic Acid
- nucleic acid analogs such as Locked Nucleic Acid (LNA), Hexitol Nucleic Acids (HNA), Altritol Nucleic Acids (ANA), and Mannitol Nucleic Acids (MNA).
- Antibodies as target molecules and specific binding regions are monoclonal antibodies, polyclonal antibodies, as well as multispecific antibodies (ie, bispecific antibodies as antibodies that recognize two or more antigens or two or more epitopes), or As long as it retains the ability to specifically bind to a target molecule, it may be a fragment of an antibody, a chemically modified antibody, a humanized antibody, a recombinant antibody, or the like.
- Fc fragments, peptides, peptidomimetics, gapmers, etc. of antibodies may also be used as specific binding regions of the target molecules, as long as they have the ability to specifically bind to the target molecules. Can be used.
- the signal generating region is a double-stranded nucleic acid, which is crosslinked with each other between the strands to maintain a stable double bond even at high temperature, and is not affected by pH, salt, ionic strength, and the like. Do not.
- a detectable label of a signaling region is any substance known in the art for generating a detectable signal, and the substance may be a single strand or double strand (or a strand) of a nucleic acid fragment constituting the signaling region. Nucleotides which are structural units of the nucleic acid fragments).
- the linear order of signals generated by each region of the signal generating region is determined by the nCounter digital analyzer (Nanter digital analyzer, Nanostring technology, USA) or US Patent No. 8,519, 115 used in the following embodiments of the present invention.
- Nikon Eclipse TE2000E Perfect Focus, 1.4 NA Plan Apo VC 60X oil-immersion lens (Nikontk, Japan), anX-) used in its related article, Nat Biotechnol.
- the signal generating region is composed of six regions and labeled using fluorescent materials capable of generating four different signals as in the following embodiments of the present invention
- 16,384 A total of 16,384 signal generating areas (or 16,384 signal probes including each signal generating area) capable of generating 6 unique signals are obtained, of which four are labeled with the same signaling material. It is obtained.
- each region constituting it in the signaling region may be determined in consideration of the extent to which the signaling substance is labeled (that is, the intensity of the generated signal).
- the length of such regions can typically range from 0.1 kb (kilo base) to 1.5 kb.
- nucleic acid amplification is prepared using three kinds of natural nucleotides (ie, dATP, dTTP and dGTP) and 100% aminoaryl-dCTP (all of which use aminoaryl-dCTP instead of dCTP).
- a 903 bp long nucleic acid fragment incorporated into aminoaryl-dCTP was labeled with a signaling material.
- the length of the region may be in the range of 0.2 kb to 0.5 kb.
- 100% of aminoaryl-dCTP is used in the embodiment of the present invention, even when 30% to 70% of aminoaryl-dCTP is used, the length of about 0.9bp may be enough to generate a sufficient signal.
- the binding of a specific binding region and a signal generating region to a target molecule is performed when both are nucleic acids (ie, when the specific binding region with the target molecule is a single-stranded nucleic acid for detecting the target nucleic acid).
- Ligase known in the art such as T4 ligase, can be linked.
- an appropriate functional group such as an amino group, a hydroxyl group, a carboxyl group, a carbonyl group, a thiol group ( functional groups (reactive groups) and introduce amide bonds, ester bonds, sulfide ester bonds, ether bonds, and the like to covalently connect the signaling region.
- a spacer and / or a fixed region may exist between the specific binding region and the signal generating region with the target molecule, as shown in FIG. 1.
- Figure 1 shows the signal probe of the present invention and the main components used in the detection method of the target molecule of the present invention using the signal probe.
- the spacer is for separating the specific binding region and the signal generating region from the target molecule, and when the specific binding region to the target molecule is bound to the target molecule, the conjugate prevents the binding from blocking the signal detection of the signal generating portion. It is to facilitate the signal detection of the signal generator.
- the spacer may be a single stranded nucleic acid, a double stranded nucleic acid, RNA, DAN, or the like, and may comprise a nucleic acid analog such as PNA or modified nucleotides.
- the length is not particularly limited as long as it can facilitate signal detection of the signal generator. It will usually be 20 to 50 bp in length.
- the fixed region is a region where one or more fixed nucleic acid molecules (or fixed molecules), which will be described later, are complementarily combined to additionally fix and straighten the signal probe of the present invention to an analysis support as described below. Consists of known sequences. Therefore, the fixed region is composed of a single-stranded nucleic acid of the sequence complementary to the fixed nucleic acid molecule, the sequence of the same substrate may be repeated two or more times so that two or more fixed nucleic acid molecules can bind.
- the fixed region may be RNA, DNA, or the like as long as it can complementarily bind to the fixed nucleic acid molecule, and may include a nucleic acid analog such as PNA or modified nucleotide, and its length may exert sufficient binding force with the fixed nucleic acid molecule. As long as it can be. In general, the sequence of the same substrate of 20 to 50bp long will be composed of 2 to 20 repetitions.
- both the spacer or the fixed region are present in the signal probe of the present invention, they are covalently coupled to the adjacent region, and the order may be any order, but the fixed region is adjacent to the signal generating region, that is, the signal generating region. It is preferable to exist on the 5 'side or the 3' side.
- the fixed region additionally fixes the signal probe of the present invention to the analytical support, the fixed region must exist adjacent to the signal generating region to fix the signal generating region to the analytical support in a linear or streached form. This is because signal detection in the signal generation area is facilitated.
- the binding tag functions to fix the signal probe of the present invention through specific binding with the binding partner to an analytical support coated with a binding partner capable of binding thereto.
- a representative material of the binding tag that can be used is biotin, and a representative binding partner for this is streptavidin.
- Streptavidin is an avidin-based antibiotic protein isolated from Streptomyces avidinii that is a tetrameric structure and can bind up to four biotin molecules.
- the binding tag may use biotin analogues such as desthiobiotin and iminobiotin as well as biotin, and the binding partner coated on the analytical support may specifically bind to biotin in addition to streptavidin.
- Streptavidin analogs such as avidin, traptavidin, and neutravidin (NeutrAvidin, Thermofisher SCIENTIFIC, USA) may be used.
- the present invention relates to a method for detecting a target molecule in a sample using a signal probe as described above.
- the detection method of the present invention includes the steps of (a) treating the signal probe on the sample to be analyzed to form a complex of a target molecule and a signal probe in the sample, and (b) detecting the signal probe of the complex. It is configured by.
- the sample to be analyzed may be any mixture or solution containing or suspected of containing the target molecule to be detected and having the need for detection.
- the sample may be a biological sample obtained from a human body or an animal, as well as a processed sample in which such a biological sample is processed to increase the concentration of the target molecule, and furthermore, environmental pollution factors such as water, food, industrial wastewater, or the like containing or containing the target powder. It may also be a sample that requires testing for toxic factors.
- a sample may include a proper diluent, a buffer solution, and may be a bacterial culture or a viral culture containing a medium or a medium component when detecting the presence of bacteria or viruses.
- the sample to be analyzed may preferably be a biological sample obtained from a human body or an animal or a processed sample thereof.
- the biological sample may be obtained from a human or animal having a need for detection because it is suspected to contain or contain target molecules to be detected such as blood, urine, saliva, semen, amniotic fluid, lymph fluid, sputum, and tissues.
- Processed samples include, for example, plasma, serum, and biological samples using protein extraction kits with high protein concentrations, samples with high nucleic acid (DNA or RNA) concentrations, tissue extracts, cells obtained from tissues, cell lysates, and cell cultures. And the like.
- the step of forming the target molecule and the signal probe complex in the sample if the sample contains a variety of target molecules using a variety of signal probes specific to each target molecule, multiple complexes It is possible to form and detect it.
- detection is understood as meaning qualitative analysis of the presence or absence of a target molecule or further including quantitative analysis of the amount and concentration of a target molecule.
- the sample is treated with a nitrocellulose membrane having a high binding affinity for the protein and then in the sample containing the target molecule.
- Adsorbing proteins to the nitrocellulose membrane may include removing the other molecules such as lipids, nucleic acids, metabolites, and the like other than the protein adsorbed onto the nitrocellulose membrane using a suitable washing solution.
- the washing solution may be purchased and used in the art or properly prepared, and the washing solution includes a surfactant and a salt.
- Surfactants include SDS, Tween 20, Tween 40, Tween 60, Tween 80, Triton X-405, Triton X-100, Tetronic 908, Cholesterol PEG 900, Polyoxyethylene Ether W-1, Span 20, Span 40, Span 85, these Mixtures may be used, and salts may be acetate, lactate, citrate, phosphate, nitrate, sulfate, chloride salts, mixtures thereof (particularly SSC, SSPE, etc.) of lithium, sodium, potassium and ammonium.
- a blocking solution containing an appropriate blocking agent such as bovine serum albumin may be included to block the non-adsorbed surface of the nitrocellulose membrane.
- This blocking step prevents the antibody from adsorbing the signal probe from degrading the detection accuracy when the specific binding region with the target molecule is used as a signal probe for the formation of a complex of the target molecule and the signal probe. It is to.
- the signal probe is processed to form a complex of the signal probe and the target molecule of step (a). In the case where the specific binding region with the target molecule is used as a signal probe that is not an antibody but an aptamer, the blocking step is not necessarily required.
- the signal probe of the present invention is cross-linked with the double-stranded nucleic acids constituting the same, so that even when heated, the signal generating region is not lost and remains stable and does not affect the accuracy of detection of target molecules.
- the signal of the signal probe is a signal generated by a signal generating material labeled on the signal probe
- the signal detecting step of the signal probe may be performed by using an appropriate device capable of detecting the signal according to the signal generating material used.
- a device may be a spectrophotometer, a fluorometer, an absorption spectrometer, a luminometer, a chemiluminometer, an actinometer, etc., depending on the characteristics of the signal.
- nCounter digital analyzer NCounter digital analyzer, Nanostring technology, USA
- a fixed molecule having a single-stranded nucleic acid sequence complementary to the fixed region of the signal probe and having a binding tag capable of binding to the complementary single-stranded nucleic acid sequence and binding to a binding partner coated on the analytical support.
- fixed nucleic acid molecules to an analytical support having a fixed signal probe.
- the binding tag of the fixed molecule biotin or a biotin analogue may be used as described above with respect to the signal probe.
- an analytical support that can be used in the method of the present invention may be formed in a shape or a shape so long as a binding partner (eg, streptavidin, etc.) to a binding tag of a signal probe can be coated on its surface through covalent or non-covalent association
- a binding partner eg, streptavidin, etc.
- Such as film form, bead form, particulate form, substrate form (such as glass slide), column form, well form, well plate form, etc., and the material may be plastic, resin, polysaccharide, silica, functionalized glass, Modified silicon, carbon, metal, inorganic glasses, membranes, nylon, natural resins, and the like.
- the material of the polymeric support is polystyrene, polyethylene glycol tetraphthalate, polyvinyl acetate, polyvinyl chloride, polyvinyl pyrrolidone, polyacrylo Nitrile (polyacrylonitrile), polymethyl methacrylate, polytetrafluoroethylene, butyl rubber, styrenebutadiene rubber, natural rubber, polyethylene, polypropylene ( polypropylene), (poly) tetrafluoroethylene, (poly) vinylidenefluoride, polycarbonate, polymethylpentene and the like.
- Figure 1 shows the main constituents, including signal probes and fixed molecules, used in the method of the present invention.
- the overall process of detecting proteins as target molecules using the nitrocellulose membrane as described above is shown in Figures 2 and 3.
- the specific binding regions with the target molecules of the signal probe are divided into the case of the antibody and the case of the aptamer, respectively.
- the detection method of the target molecule of the present invention may be made by using a capture probe in addition to the signal probe as described above.
- capture detection method of the present invention (a) by processing a signal probe and a capture probe that specifically binds to the target molecule to the sample to be analyzed the target Forming a complex of a molecule with the signal probe and the capture probe, and obtaining a mixture comprising the complex, the complex comprising the signal probe, the capture probe, etc., and (b) And detecting the signal probe.
- the capture probe is a region (i.e., an epitope) of a target molecule to which the signal probe specifically binds and a region that specifically binds to another region and magnetic particles (or magnetic beads) in the region.
- a region i.e., an epitope
- the signal probe specifically binds
- a region that specifically binds to another region and magnetic particles (or magnetic beads) in the region has a connected configuration, a schematic diagram of which is shown in FIG.
- Magnetic particles are proteins, nucleic acids, cells in the art as disclosed in US Pat. No. 5,665,554, US Pat. No. 6,0279.45, US Pat. No. 7,078,224, Korean Patent Publication No. 2006-0061494, Korean Patent No. 0541282, and the like.
- the magnetic particles that have been used for the separation of biomaterials are iron oxide magnetic particles, and as such iron oxide magnetic particles, magnetite (Fe 3 O 4 ), maghemite (Fe 2 O 3 ), hematite (mematite; Fe 2 O 3 ) and the like have been used.
- Magnetic particles can be modified with silica, polymer, gold, and silver nonmagnetic materials to be used for separation of biomolecules such as proteins and nucleic acids, and can be combined with biomolecules such as proteins and nucleic acids.
- a functional group such as a carboxyl group, an epoxy group, a tosyl group, an amino group, or a siloxane group, or a biotin or streptavidin binding substance needs to be introduced.
- Magnetic particles having such properties or methods for producing the same are well known in the art, and are described in US Pat. No. 6,027,945, US Pat. No. 6,673,631, US Pat. No. 7,183,002, Japanese Patent No. 3,253,638, and Japanese Patent Laid-Open No. 2001-136970. And many other documents, such as Korean Patent Publication No. 2009-0088299, and Dynabeads magnetic beads coated with streptavidin (Thermo Fisher Scientific, USA), DYNAL M-270 and DYNAL M-280 having a tosyl group introduced therein. (Dynal Biotech ASA, Norway) and the like are commercially available.
- the capture probe may have a specific binding region with its target molecule covalently linked to such a magnetic particle through a functional group or through a noncovalent bond between biotin and streptavidin.
- the specific binding region of the capture probe with the target molecule is recognized and bound by the specific binding region of the signal probe with the target molecule in order to prevent competitive binding to the target molecule and the specific binding region of the signal probe. It is designed to recognize and bind a site different from the site to be.
- the step (a) is performed by processing a signal probe and a capture probe on the sample to be analyzed, in which case a complex between the target molecule, the signal probe, and the capture probe is formed, together with the A mixture comprising a complex, a signal probe without forming a complex, a capture probe without forming a complex, a nontarget molecule, and the like is obtained.
- the next step is to detect the signal probe of the complex in the mixture (b).
- the detection of the signal probe is that the capture probe contains magnetic particles, so when the mixture is applied to the magnet, only the capture probe which does not form a complex with the complex including the capture probe binds to the magnet.
- signal probes and non-target molecules which do not form a complex are removed.
- the signal probe After bonding the composite or the like to the magnet, only the signal probe is separated from the composite, which is possible by heating or treatment with a surfactant as described above. As described above, the double-stranded nucleic acid constituting the signal probe is crosslinked with each other to maintain a stable state even when heated.
- the detecting step of the signal probe of step (b) includes only a capture probe that does not form a complex with the complex by applying a magnet to the mixture (b-1). And (b-2) separating the signal probe from the complex bound to the magnet, and (b-3) detecting the separated signal probe.
- a capture probe that does not form a complex with the complex by applying a magnet to the mixture (b-1).
- b-2 separating the signal probe from the complex bound to the magnet
- (b-3) detecting the separated signal probe.
- the detection method of the target molecule can be made by using a capture competition molecule in addition to the signal probe as shown in Figures 6 and 7.
- the method using the capture competition molecule of the present invention (hereinafter referred to as "competition detection method of the present invention” for convenience) (a) by processing a signal probe and a capture competition molecule that specifically binds the target molecule to the sample to be analyzed. Forming a complex of the capture competition molecule and the signal probe, obtaining a mixture comprising the complex, and (b) detecting the signal probe of the complex in the mixture.
- the mixture may include a complex of a target molecule and a signal probe, a signal probe that does not form a complex, a competition molecule that does not form a complex, a target molecule that does not form a complex, and a nontarget molecule, in addition to a complex of a capture competition molecule and a signal probe.
- the capture competition molecule has a region that specifically binds to the same site (ie, an epitope) of the target molecule to which the signal probe specifically binds, and a structure in which magnetic particles are connected to the region.
- the capture competition molecule will generally be the same molecule as the target molecule, but as long as it has the same site as the site of the target molecule (ie epitope) to which the signal probe specifically binds, it can compete in binding with the signal probe. It may be.
- Such analogous molecules include proteins in which the target protein is fused with another protein (Fc of an antibody).
- the capture competition molecule has a binding site of the same signal probe as the target molecule, so it competes with the target molecule for binding to the signal probe, and when the signal probe is processed to the sample in a limited amount and the capture competition molecule is quantified and processed, the capture competition
- the detection result of the molecule may provide information (ie, presence or absence of the target molecule, concentration, etc.) of the target molecule in the sample to be analyzed.
- the "signal probe is processed to the sample in a limited amount” means that it is processed below the amount capable of detecting both the capture competition molecule and the target molecule, and theoretically, the concentration (quantitative value) of the capture competition molecule quantified This means that the sample is treated with a concentration capable of detecting less than the sum of the estimated concentrations (quantitative values) of the target molecules present in the sample to be analyzed, but the actual processed signal probes bind to the capture competition molecules or target molecules. And may be processed beyond the summation value. However, in general, since it is difficult to estimate the concentration of the target molecule in the sample, the limit amount of the signal probe will be a concentration capable of detecting below the concentration of the captured competitive molecule.
- detecting the signal probe of the complex in the mixture of step (b) can be performed as in the capture detection method of the present invention.
- the details of the (b-3-i) fixation of the signal probe to the support for analysis and (b-3-ii) the detection step may refer to the descriptions related to the protein detection method using the nitrocellulose membrane.
- the present invention uses the stable double-stranded nucleic acid signal probe in the detection of the target molecule to form a complex with the target molecule of the target molecule, and then by separating only the signal probe from the complex by heating or the like and detecting the signal probe It is possible to provide a method for detecting a target molecule.
- FIGS. 2 and 3 show step by step the detection method of the protein of the present invention using a nitrocellulose membrane.
- 4 and 5 show step by step detection method of the target molecule using the capture probe.
- 6 and 7 illustrate stepwise detection methods of target molecules using capture competition molecules.
- nCounter digital analyzer 10 is an image obtained by using a signal probe of the present invention to detect bacteria and the results using an nCounter digital analyzer (NCounter digital analyzer, Nanostring technology, USA).
- FIG. 11 is a schematic diagram showing that the signal probe of the present invention is imaged in the nCounter digital analyzer (NCounter digital analyzer, Nanostring technology, USA).
- FIG. 12 is a graph of analyzing two types of standard target molecules using the signal probe of the present invention and displaying the target molecule amounts and signal values in log vs. log scale.
- FIG. 13 is a graph in which 13 types of target molecules are analyzed twice using the signal probe of the present invention, and the results are displayed on the log-log scale of the target molecules and the signal values.
- the "signal probe” is described as “first probe” or used interchangeably in the following examples, and the “signal generation area” is described as “color indicator bar code” or as used interchangeably with the “signal probe”.
- Specific binding regions with target molecules "have been described as” first probe “or” first ligand "or in combination with them.
- Nucleotide sequence information of M13 DNA which is a skeleton of signal tag, was obtained from GenBank data system (http://www.ncbi.nlm.nih.gov) (Accession number NC_003287).
- one type selected from four types of fifth domain signal tags is divided into four tubes, each containing a final concentration of 10 ug / mL, and each tube containing four types of sixth domain signal tags having a final concentration of 10 ug / mL.
- Put each mL into the final volume of 100L T4 ligase reaction solution 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, pH 7.5
- the remaining three types of the fifth domain signal tag were also processed in the same manner as described above to mix all four types of the fifth domain signal tag and four types of the sixth domain signal tag, respectively. , 6 domain mixed solution.
- FIG. 9 An image of the result of electrophoresis of the reaction product for each reaction step is shown in FIG. 9.
- 5'-color indicator barcode-spacer-first probe-3 ' An unfixed first probe was made with the structure of 5'-color indicator barcode-spacer-first probe-3 '.
- 5 'and 3' are used to mean the direction or order of the arrangement of nucleic acids, such as color indicator bar code, spacer, such as when the nucleic acid is used as a component of the probe.
- reaction solution 50 mM Tris-HCl, 10 mM MgCl 2, with 10 ul of 5'-spacer-first probe-3 'structure at 1 mg / ml and 10 ul of color indicator barcode at 1 mg / ml
- reaction solution 50 mM Tris-HCl, 10 mM MgCl 2, with 10 ul of 5'-spacer-first probe-3 'structure at 1 mg / ml and 10 ul of color indicator barcode at 1 mg / ml
- 5 unit / uL T4 ligase N4 ligase
- 5'-Spacer-NH 2 a spacer of single stranded nucleic acid with the next reactive group (NH 2 ), was custom made (Integrated DNA Technologies, USA). Next, the activated antibody and the spacer having the reactive group were reacted in an N-succinimidyl-S-acetyl-thioacetate solution to prepare a 5'-spacer-antibody-3 'structure.
- reaction solution with 10 ul of 5'-spacer-antibody-3 'structure at 1 mg / ml and 10 ul of color indicator barcode at 1 mg / ml (50 mM Tris-HCl, 10 mM MgCl2, 1 2 uL of 5 unit / uL T4 ligase (NEB, USA) was added to mM ATP, 10 mM DTT, pH 7.5) to prepare a non-fixed first probe for the detection of proteins and the like.
- the fixed first probe was made with a 5'-first probe-spacer-fixed region-color indicator barcode-biotin-3 'structure.
- the fixed region is composed of a repeating sequence with a known sequence, and a fixed molecule (ie, a fixed nucleic acid molecule) comprising a sequence complementary to the fixed region is used to fix the first probe to the support by complementarily binding.
- a fixed first probe using a single stranded nucleic acid as a first probe was prepared as follows. First, a 5'-spacer-fixed region-3 'construct of single-stranded nucleic acid was prepared and prepared (Integrated DNA Technologies, USA). The reaction of adding biotin to the following color indicator barcodes was made using the Thermo Scientific Biotin 3 End DNA Labeling Kit (Thermo Scientific, USA) to prepare 5'-color indicator barcode-biotin-3 'constructs.
- a fixed first probe using an antibody as the first probe was prepared as follows. First, an antibody to which a 5'-color indicator barcode-biotin-3 'structure and a reactive group (SH group) were added was prepared in the same manner as above, and 5'-NH, a single-stranded nucleic acid having a reactive group (NH 2 ), was prepared. The 2 -spacer-fixed region-3 ′ construct was made to order and prepared (Integrated DNA Technologies, USA).
- An unfixed first probe using an aptamer as the first probe was prepared as follows. First, the 5'-color indicator barcode-biotin-3 'construct was prepared in the same manner as above, and the single-stranded nucleic acid of the 5'-aptammer-spacer-fixed region-3' was prepared by order production (Integrated DNA Technologies Inc.). , United States of America).
- the second probe was prepared by combining magnetic beads with a capture probe or a capture probe and a second probe, which is a specific binding region with the target molecule, and a harvesting material, and a competition molecule, with a target molecule (or target molecule). It was prepared by combining magnetic beads with a competitive target molecule analog) and a harvesting material.
- a second probe, a single stranded nucleic acid or an aptamer, a second probe was prepared by using biotin and streptavidin as a mediator to the second probe.
- the reaction of adding biotin to the previously prepared mononucleic acid or aptamer was performed using the Thermo Scientific Biotin 3 End DNA Labeling Kit (Thermo Scientific, Inc., USA). Prepared. Specifically, according to the standard method provided by the manufacturer in a reaction mixture of 45 uL (100 mM Potassium Acetate, 20 mM Tris) in which 100 ul of the structure of 1 mg / ml concentration and 5 uL of Biotin-11-UTP were mixed at a concentration of 5 uM.
- the second probe wherein the second probe is an antibody
- 100 ⁇ g of antibody and 5 mg of Tosyl group (Tosylactivated) magnetic beads (M-280 Tosylactivated magnetic beads, Dynal Biotech ASA, Norway) were added to the buffer solution (0.1 M borate buffer, pH 9.5).
- the reaction was carried out at room temperature for 48 hours.
- Magnetic beads to which antibodies were bound through a tosyl group were separated using a magnet, and the beads were washed with the same buffer solution to remove unbound antibodies.
- the magnetic beads (hereinafter referred to as capture probes) in which the molecules were bonded were inactivated tosyl groups not bound to the molecules by washing at 37 ° C. for 4 hours with 0.1% BSA solution (Bovine Serum Albumin, Sigma, USA) after washing. . After washing several times, the magnetic beads were mixed with the buffer solution (0.1 M PBS, pH 7.4) and stored at 4 ° C.
- Capture competition molecules whose competition molecules are single-stranded nucleic acids are used for detection of nucleic acids that are target molecules, which were prepared in the same manner as the preparation of the second probe, wherein the second probe is a single-stranded nucleic acid or aptamer.
- Capture competition molecules whose competition molecules are proteins are used to detect proteins that are target molecules, which were prepared in the same manner as the preparation of the second probe wherein the second probe is a single-stranded nucleic acid or aptamer.
- the competition molecule used the same protein as the target protein.
- the fixed molecule was prepared by custom-made a single-stranded nucleic acid labeled with a biotin at the 5 'end of the base sequence complementary to the repeat sequence constituting the fixed region of the first probe (Integrated DNA Technologies, USA).
- Representative food poisoning bacteria E. coli, Salmonella, Listeria and Staphylococcus were detected using a fixed first probe prepared using the antibodies of Table 2 and the aptamer of Table 3 as the first probe (ligand).
- Antibodies that bind to food poisoning surface molecules Antibody type Catalog Number Supplier E. coli / Anti-E. coli antibody ab25823 Abcam loves Listeria / Anti-Listeria Antibody 01-90-95 KPL Salmonella CSA-1 / Anti-Salmonella CSA-1 Antibody 01-91-99 KPL
- the reaction solution is 10 mM PBS buffer (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl pH 7.4) for antibody ligands and Selex buffer (20 mM Tris-Cl buffer, pH 7.6 contained 100 mM NaCl, for aptamer ligands). 2 mM MgCl 2 , 5 mM KCl, 1 mM CaCl 2 and 0.02% Tween) were used.
- the reaction solution contained 0.05 to 0.2% (w / v) of sodium azide for inhibiting bacterial growth and 0.1 to 0.3% (w / v) of bovine serum albumin for inhibiting nonspecific binding. The reaction was carried out at a temperature of 20-30 ° C.
- 70 ul of the sample containing bacteria was mixed with 15 ul of the first probe combined with biotin and reacted by shaking for 30 minutes.
- 20 ul of the reaction solution was treated with a streptavidin-coated glass slide (Nanocs, USA), and the glass slide was washed three times with a washing solution containing 0.1X SSPE and 0.1% tween-20 to bind bacteria.
- the first probe that did not or was in nonspecific binding was removed. Spots where the presence signal of the bacteria in the complex formed by covering the cover slip and the first probe combined with the bacteria are generated, using the manufacturer's protocol using a nCounter digital analyzer (Nanostring technology, USA). And imaged according to FIG. 9.
- Sequence information of the target molecules ⁇ -actin, IL17, and IL17R mRNA can be obtained from the GenBank data system (http://www.ncbi.nlm.nih.gov) (Accession number of IL17 is NM_002190, And Accession number of IL17RA: NM_014339).
- Probe Sequence for Target mRNA kinds First probe (5'-3 ') Second probe (5'-3 ') ⁇ -actin mRNA gggcgacgaggcccagagcaagaga (SEQ ID NO: 19) ggcatcctcaccctgaagtacccca (SEQ ID NO: 20) IL17 mRNA ccctcaggaaccctcatccttcaa (SEQ ID NO: 21) gacagcctcatttcggactaaactc (SEQ ID NO: 22) IL17RA mRNA ggagcagaagcctcccagccactag (SEQ ID NO: 23) ccttttgggctcagtctctccaata (SEQ ID NO: 24)
- Human cartilage tissue (Promocell, Germany) was used for the sample.
- the target molecule mRNA in the sample was isolated using an AllPrep DNA / RNA / Protein Mini kit (Qiagen, USA).
- cartilage tissue was dissolved in a buffer provided by the manufacturer according to the manufacturer's protocol, and then the dissolved sample was treated in a column and centrifuged to bind RNA to the column membrane.
- RNA separation on the column membrane was performed by washing the column with RNA, extracting RNA from the membrane, and then centrifuging to harvest RNA.
- the first probe-target mRNA-second probe complex was induced by hybridization by mixing and shaking the first probe 200 ng / uL and the second probe 200 ng / uL to 100 ng / uL total RNA.
- Hybridization reaction was carried out at 65 °C conditions in a reaction solution containing 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS) and 1 mM EDTA.
- SDS sodium dodecyl sulfate
- the reaction solution was then treated with a magnet to induce the fixation of the second probe with the magnet by the magnetic beads, followed by washing with a washing solution to remove the unbound first probe and the non-target RNA.
- the wash was performed once at 48 ° C using 6X standard saline citrate / 0.1% SDS, once at 68 ° C using 0.1X SSC / 0.1% SDS, and once at 42 ° C using 0.2X SSC / 0.1% SDS. Three times were performed.
- a magnet containing 0.1X SSPE and 0.1% tween-20 was treated in a magnet bound to the first probe-target mRNA-second probe complex and heated at 95 ° C. for 5 minutes to induce separation of the first probe from the complex. Then, the supernatant containing the first probe was harvested.
- the first probe was immobilized on a streptavidin-coated cover slip using a molecular counting analyzer, nCounter digital analyzer (Nanostring technology, USA), according to the manufacturer's protocol. Spots were imaged to detect and quantify.
- the first probe was further immobilized on the surface by adding 60 uL of 500 nM fixed molecule to the unrolled first probe to induce complementary binding to the fixed region including the repeat sequence of the first probe. The current was held for 5 minutes during this immobilization process.
- the TAE solution was removed and imaging was prepared by adding SlowFade reagent (Invitrogen), an anti-photobleaching reagent. After this preparation, four images were acquired at four different excitation wavelengths (480, 545, 580, 622) corresponding to four fluorescent materials through the analyzer of the analyzer. Spatial clustering was performed to obtain the images for the first probe as shown in the schematic diagram of FIG. 11. Imaging Procedure The resolution of the analyzer was set to 600 field of view (FOV).
- the data was downloaded from the analyzer and analyzed on Excel according to the analysis instructions provided by the manufacturer. Data were initially normalized to the reference and target molecules in the sample using the positive assay control standard curve provided. Normalized values were averaged over the target molecule values using the values of the reference materials included in the sample. Quantitative values of target molecules were calculated by averaging the results of three replicate performance analysis.
- the detection reaction was performed for the target molecules of Table 5 below using only the fixed first probe including the polyclonal antibody of Table 5 as the first probe for the target molecule.
- the overall process of this protein detection reaction can be seen in FIGS. 2 and 3.
- Target Molecules and Antibodies Target molecule / antibody Catalog Number manufacturer NGF / NGF Anti-NGF / NGF ⁇ Antibody OKBB00229 Aviva Systems Biology Amyloid beta (A4) Precursor Protein (APP) Anti-Amyloid beta (A4) Precursor Protein (APP) antibody ab12266 Abcam (Tau) / Anti- (Tau) antibody T6402 SIGMA phospho-Tau (pSer400) / Anti-phospho-Tau (pSer400) antibody T1700 SIGMA C Reactive Protein (CRP) / Anti-C Reactive Protein (CRP) ab99995 abcam TGF alpha / Anti-TGF alpha antibody ab9585 abcam IL1 beta / Anti-IL1 beta antibody ab2105 abcam Serum Amyloid A / Anti-Serum Amyloid A antibody ab200584 abcam p53 / p53 Antibody (DO-7) MA5-12557 abcam CEACAM5 / CEACAM5 Polyclonal Antibody MBS170144 Bio
- a solution containing 100 ug / ml of the target molecule of Table 5 was prepared using 10 mM PBS buffer (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl pH 7.4), and the solution was diluted in steps.
- the final biomolecule concentrations were 1,000 pg / mL, 100 pg / mL, 10 pg / mL, 0.1 pg / mL and 0 pg / mL.
- Analytical mixed samples were prepared by mixing the above diluted solutions for various biomolecules at various concentrations.
- the fixed first probe solution was prepared to contain the first probe at a concentration of 200 ng / ul using 10 mM PBS buffer (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl pH 7.4).
- Nitrocellulose membrane disc was added to the reaction solution containing the sample to be shaken for 30 minutes to allow the protein in the sample to be adsorbed onto the membrane.
- the disc was washed with 150 uL of 0.1X SSPE / 0.1% tween-20 solution and placed in a Blocking solution [washing solution with 2% (w / v) Bovine Serum Albumin (BSA)] to react.
- 70 ul of the fixed first probe solution for each target molecule was added thereto, and stirred for 1 hour to induce complex formation between the target molecule and the first probe.
- 150 ⁇ L of 0.1X SSPE / 0.1% tween-20 solution was added to the disk to remove excess first probe that did not form a complex and first probe that formed a nonspecific complex, and washed three times.
- 0.1X SSPE / 0.1% tween-20 solution was added to the washed disc and heated at 95 ° C. for 5 minutes to induce separation of the first probe from the complex. Then, the supernatant containing the first probe was harvested.
- the first probe was streaked in accordance with the manufacturer's protocol using an nCounter digital analyzer (NCounter digital analyzer, Nanostring technology, USA) in the same manner as in Example 3-1.
- Tabidine was fixed on the coated slip and the fixed spots were imaged to detect and quantify.
- the polyclonal antibody of Table 5 Similar to the fixed first probe comprising the polyclonal antibody of Table 5 as the first probe for the target molecule, the polyclonal antibody of Table 5 as the second probe for each target molecule
- the detection probe for the target molecule of Table 5 was carried out using 2 probes. The overall process of this protein detection reaction can be seen in FIGS. 4 and 5.
- Analytical samples were prepared in the same manner as in Example 4-1. To 25 ul of the sample, a mixture of 70 ul of the fixed first probe solution and 70 uL of the second probe solution for each target molecule was stirred for 1 hour while shaking to induce complex formation between the first probe-target molecule and the second probe. It was. The reaction solution was then treated with a magnet to induce fixation of the second probe with a magnetic bead to the magnet, followed by washing with a wash solution to remove unbound first probe and non-target molecules. The washing was performed three times using 150 uL of 0.1X SSPE / 0.1% tween-20 solution.
- the first probe was streaked in accordance with the manufacturer's protocol using an nCounter digital analyzer (NCounter digital analyzer, Nanostring technology, USA) in the same manner as in Example 3-1.
- Tabidine was fixed on the coated slip and the fixed spots were imaged to detect and quantify.
- FIG. Very high reproducibility was observed between pg / mL.
- the analytical results also showed that the linear regression correlation coefficient of concentration vs. count was linear with ⁇ 0.989 logo at 0.1 log or more of concentration.
- a detection reaction is performed on the target molecules of ⁇ Table 5> by using a first probe having the antibody of Table 6 as the first probe and a capture competition molecule using each protein of Table 5 as a competition molecule. It was.
- the overall process of this protein detection reaction can be seen in FIGS. 6 and 7.
- the first probe was streaked in accordance with the manufacturer's protocol using an nCounter digital analyzer (NCounter digital analyzer, Nanostring technology, USA) in the same manner as in Example 3-1.
- Tabidine was fixed on the coated slip and the fixed spots were imaged to detect and quantify.
- the quantitative result of the target molecule was obtained using the standard curve from the quantitative result of the capture competition molecule.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
아댑터의 종류 | 염기서열 | 일렬번호 |
Eco RI/Sma I Adaptor | 5'-AATTCCCCGGG--3' 3-GGGGCCCp-5' | 서열번호 3서열번호 4 |
Hind III/Not I Adaptor | 5'-AGCTTGCGGCCGC--3' 3-ACGCCGGCGp-5' | 서열번호 5서열번호 6 |
Xho I/Pst I Adaptor | 5'-TCGAGCTGCAGG--3' 3-CGACGTCCp-5' | 서열번호 7서열번호 8 |
Sal I/Bam HI Adaptor | 5'-TCGACGGATCC--3' 3-GCCTAGGp-5' | 서열번호 9서열번호 10 |
항체 종류 | 카탈로그번호 | 공급회사 |
E. coli / Anti-E. coli antibody | ab25823 | Abcam 사 |
Listeria / Anti-Listeria Antibody | 01-90-95 | KPL 사 |
Salmonella CSA-1 / Anti-Salmonella CSA-1 Antibody | 01-91-99 | KPL 사 |
식중독균 | 염기서열(5'→3') | 일련번호 | 비고 |
대장균(e.coli) | CGCAGUUUGC GCGCGUUCCA AGUUCUCUCA UCACGGAAUA | 서열번호 13 | 대한민국등록특허 10-0730359 |
ACACUGCGUG CUUACGACUU CUGGUCCCAU CAUUCGGCUA | 서열번호 14 | ||
AGUUCGAUGA GGGUGACACC GCCAGGAGUG UUUGCUAGAC | 서열번호 15 | ||
Salmonella typhimurium | AGGTCTGTAGGTCTGCGGGGCGTGG | 서열번호 16 | 대한민국등록특허 10-1459547 |
CAGCCAGGATGGGAGGTCTGTAGGTCTGCGGGGCGTGG | 서열번호 17 | ||
Staphylococcus aureus | GCAATGGTACGGTACTTCCGGGCTGGCCAGATCAGACCCCGGATGATCATCCTTGTGAGAACCACAAAAGTGCACGCTACTTTGCTAA | 서열번호 18 | Aptagen사 |
종 류 | 제1 프로브 (5'-3') | 제2 프로브 (5'-3') |
β-actin mRNA | gggcgacgaggcccagagcaagaga(서열번호 19) | ggcatcctcaccctgaagtacccca(서열번호 20) |
IL17 mRNA | ccctcaggaaccctcatccttcaaa(서열번호 21) | gacagcctcatttcggactaaactc (서열번호 22) |
IL17RA mRNA | ggagcagaagcctcccagccactag(서열번호 23) | ccttttgggctcagtctctccaata(서열번호 24) |
표적분자/항체 | 카탈로그번호 | 제조사 |
NGF/NGF Anti-NGF/NGFβ antibody | OKBB00229 | Aviva Systems Biology |
Amyloid beta (A4) Precursor Protein (APP) Anti-Amyloid beta (A4) Precursor Protein (APP) antibody | ab12266 | Abcam |
(Tau) / Anti- (Tau) antibody | T6402 | SIGMA |
phospho-Tau (pSer400) / Anti-phospho-Tau (pSer400) antibody | T1700 | SIGMA |
C Reactive Protein (CRP)/ Anti-C Reactive Protein (CRP)antibody | ab99995 | abcam |
TGF alpha / Anti-TGF alpha antibody | ab9585 | abcam |
IL1 beta / Anti-IL1 beta antibody | ab2105 | abcam |
Serum Amyloid A / Anti-Serum Amyloid A antibody | ab200584 | abcam |
p53 / p53 Antibody (DO-7) | MA5-12557 | abcam |
CEACAM5 / CEACAM5 Polyclonal Antibody | MBS170144 | BioSource |
alpha Fetoprotein / alpha Fetoprotein antibody (alpha-Fetoprotein) (N-Term) | ABIN356914 | Biocompare |
E. coli Enoyl-ACP Reductase/ Anti-E. coli Enoyl-ACP Reductase antibody | Sino Biological Inc. 중국 | |
Phototropin 1 / Anti-Phototropin 1 antibody | Cosmo Bio Co. Ltd. 일본 |
표적분자 | 일렬번호 | 실제양(pg/mL) | 측정양(pg/mL) |
NGF/NGF | 1 | 12.0 | 12.5 |
Amyloid beta (A4) Precursor Protein (APP) | 2 | 1.0 | 0.8 |
Tau | 3 | 1.0 | 0.8 |
phospho-Tau (pSer400) | 4 | 0.2 | 0.2 |
C Reactive Protein (CRP) | 5 | 130 | 125.5 |
TGF alpha | 6 | 6.0 | 6.2 |
IL1 beta / Anti-IL1 beta antibody | 7 | 40.0 | 38.1 |
Serum Amyloid A | 8 | 5.0 | 5.0 |
p53 | 9 | 2.5 | 2.5 |
CEACAM5 | 10 | 2.0 | 1.9 |
alpha Fetoprotein | 11 | 0.5 | 0.6 |
E. coli Enoyl-ACP Reductase | 12 | 80.0 | 81.9 |
Phototropin 1 | 13 | 10.0 | 9.5 |
Claims (41)
- (i) 표적분자에 특이적으로 결합하는 영역과(ii) 그 표적분자와의 특이적 결합영역에 결합된 신호발생영역을 포함하되,그 신호발생영역은 서로 상보적으로 가교결합된 이중가닥 핵산으로 그 이중가닥 핵산에는 동일한 신호발생물질로 표지되거나 서로 다른 신호발생물질로 표지된 2개 이상의 영역이 존재하는표적분자에 고유한 신호를 발생시킬 수 있는 이중가닥 핵산 신호 프로브.
- 제1항에 있어서,상기 2개 이상의 영역은 그 하나 이상의 영역이 나머지 영역과는 다른 신호를 발생시키는 신호발생물질로 표지된 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 신호발생영역인 이중가닥 핵산은 완전한 이중가닥 핵산 또는 부분적 이중가닥 핵산인 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 표적분자와의 특이적 결합영역은 단일가닥 핵산, 항체, 항원 또는 압타머인 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 신호발생물질은 서로 다른 색상을 가진 2종류 이상의 형광물질인 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,고정영역이 기지의 서열로 신호발생영역에 인접하여 연결된 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,고정영역이 기지의 서열로 상기 신호발생영역에 인접하여 추가로 연결되고,기지의 서열이 2회 반복하여 이루어진 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 표적분자와의 특이적 결합영역과 상기 신호발생영역 사이에 스페이서가 포함되어 연결된 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 표적분자의 특이적 결합영역 반대쪽에 결합 태크가 연결된 것을 특징으로 하는신호 프로브.
- 제1항에 있어서,상기 표적분자의 특이적 결합영역 반대쪽에 결합 태크가 연결되고,그 결합 태그는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는신호 프로브.
- (a) 분석 대상 시료에 표적분자와의 특이적 결합영역을 가진 신호 프로브를 처리하여 시료 중의 표적분자와 신호 프로브의 복합체를 형성시키는 단계, 및(b) 그 복합체의 신호 프로브를 검출하는 단계를 포함하되,상기 신호 프로브는 (i) 표적분자에 특이적으로 결합하는 영역과 (ii) 그 표적분자와의 특이적 결합영역에 결합된 신호발생영역을 포함하고, 그 신호발생영역은 서로 상보적으로 가교결합된 이중가닥 핵산으로 그 이중가닥 핵산에는 동일한 신호발생물질로 표지되거나 서로 다른 신호발생물질로 표지된 2개 이상의 영역이 존재함으로써,상기 신호 프로브의 검출 단계는 상기 신호발생영역의 신호를 검출함에 의해 수행되는분석 대상 시료 중의 표적분자의 검출방법.
- 제11항에 있어서,상기 표적분자와의 특이적 결합영역은 단일가닥 핵산, 항체, 항원 또는 압타머인 것을 특징으로 하는검출방법.
- 제11항에 있어서,상기 신호 프로브의 검출 단계는 (i) 상기 복합체로부터 신호 프로브를 분리하는 단계, 및 (ii) 그 분리된 신호 프로브의 신호를 검출하는 단계를 포함하는검출방법.
- (a) 분석대상 시료를 니트로셀룰로오스 막에 처리하여 시료 중의 단백질들을 니트로셀룰로오스 막에 흡착시키는 단계,(b) 상기 단백질이 흡착된 니트로셀룰로오스 막에 차단제를 처리하여 단백질이 비흡착된 니트로셀룰로오스 표면을 차단시키는 단계,(c) 상기 차단된 니트로셀룰로오스 막에 표적단백질과의 특이적 결합영역을 가진 신호 프로브를 처리하여 시료 중의 표적단백질과 신호 프로브의 복합체를 형성시키는 단계, 및(d) 그 복합체의 신호 프로브를 검출하는 단계를 포함하되,상기 신호 프로브는 (i) 표적단백질에 특이적으로 결합하는 영역과 (ii) 그 표적단백질과의 특이적 결합영역에 결합된 신호발생영역을 포함하고, 그 신호발생영역은 서로 상보적으로 가교결합된 이중가닥 핵산으로 그 이중가닥 핵산에는 동일한 신호발생물질로 표지되거나 서로 다른 신호발생물질로 표지된 2개 이상의 영역이 존재함으로써,상기 신호 프로브의 검출 단계는 상기 신호발생영역의 신호를 검출함에 의해 수행되는분석대상 시료 중의 표적단백질의 검출방법.
- 제14항에 있어서,상기 표적분자와의 특이적 결합영역은 항체 또는 항원인 것을 특징으로 하는검출방법.
- 제14항에 있어서,상기 (a) 단계 후에 니트로셀룰로오스 막에 흡착된 단백질 이외의 다른 분자들을 제거하기 위한 세척 단계가 수행되는 것을 특징으로 하는검출방법.
- 제14항에 있어서,상기 (c) 단계 후에 비특이적 결합 분자를 제거하기 위한 세척 단계가 수행되는 것을 특징으로 하는검출방법.
- 제14항에 있어서,상기 (d) 단계의 신호 프로브 검출 단계가, (d-1) 상기 복합체로부터 신호 프로브를 분리시키는 단계, 및 (d-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되는 것을 특징을 하는검출방법.
- 제14항에 있어서,상기 신호 프로브는 그 표적분자의 특이적 결합영역 반대쪽에 결합 태크가 연결되어 있고,상기 (d) 단계의 신호 프로브 검출 단계가, (d-1) 상기 복합체로부터 신호 프로브를 분리시키는 단계, 및 (d-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되며,상기 (d-2) 신호 프로브 검출 단계는(d-2-i) 그 분리된 신호 프로브를, 그 신호 프로브의 결합 태그를 통해 그 결합 태그에 대한 결합 파트너가 코팅되어 있는 분석용 지지체에 처리하여 결합 태그와 결합 파트너의 특이적 결합을 통해 분석용 지지체에 고정시키는 단계와, (d-2-ii) 그 지지체에 고정된 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제19항에 있어서,상기 결합 태그는 그 결합 태그는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
- 제19항에 있어서,상기 결합 파트너는 스트렙타비딘 또는 스트렙타비딘 유사체인 것을 특징으로 하는검출방법.
- 제19항에 있어서,고정영역이 기지의 서열로 상기 신호발생영역에 인접하여 추가로 연결되어 있고,상기 (d-2-ii) 신호 프로브의 신호 검출 단계는상기 고정영역에 상보적인 단일가닥 핵산 서열을 가지고 그 서열에 상기 결합 파트너와 특이적으로 결합할 수 있는 결합 태그를 가진 고정핵산분자를 상기 지지체에 처리하는 단계, 및그 처리 단계 후 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제22항에 있어서,상기 고정핵산분자의 결합 태크는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
- (a) 분석대상 시료에 그 표적분자에 특이적으로 결합하는 신호 프로브와 그 신호 프로브가 특이적으로 결합하는 표적분자의 부위와 다른 부위에 특이적으로 결합하는 영역과 그 영역에 자성입자가 연결된 포획 프로브를 처리하여 상기 표적분자와 상기 신호 프로브 그리고 상기 포획 프로브의 복합체를 형성시킴과 함께, 그 복합체를 포함하고 복합체를 형성하지 않은 신호 프로브와 포획 프로브를 포함하는 혼합물을 얻는 단계, 및(b) 그 혼합물 중의 복합체의 신호 프로브를 검출하는 단계를 포함하되,상기 신호 프로브는 (i) 표적단백질에 특이적으로 결합하는 영역과 (ii) 그 표적단백질과의 특이적 결합영역에 결합된 신호발생영역을 포함하고, 그 신호발생영역은 서로 상보적으로 가교결합된 이중가닥 핵산으로 그 이중가닥 핵산에는 동일한 신호발생물질로 표지되거나 서로 다른 신호발생물질로 표지된 2개 이상의 영역이 존재함으로써,상기 신호 프로브의 검출 단계는 상기 신호발생영역의 신호를 검출함에 의해 수행되는분석대상 시료 중의 표적단백질의 검출방법.
- 제24항에 있어서,상기 표적분자와의 특이적 결합영역은 단일가닥 핵산, 항체, 항원 또는 압타머인 것을 특징으로 하는검출방법.
- 제24항에 있어서,상기 (b) 신호 프로브 검출 단계는(b-1) 상기 혼합물 중의 복합체로부터 신호 프로브만을 분리시키는 단계, 및(b-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되는 것을 특징을 하는검출방법.
- 제24항에 있어서,상기 (b) 신호 프로브 검출 단계는(b-1) 상기 혼합물 중의 복합체로부터 신호 프로브만을 분리시키는 단계, 및(b-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되고,상기 (b-1) 신호 프로브만을 분리시키는 단계는(b-1-i) 상기 혼합물에 자석을 적용하여 상기 복합체와 복합체를 형성하지 않은 포획 프로브만을 자석에 결합시켜 혼합물의 나머지 성분을 제거하는 단계,(b-1-ii) 자석에 결합되어 있는 복합체로부터 신호 프로브만을 분리시키는 단계를 포함하여 수행되되는 것을 특징으로 하는검출방법.
- 제27항에 있어서,상기 신호 프로브는 그 표적분자의 특이적 결합영역 반대쪽에 결합 태크가 연결되어 있고,상기 (b-2)의 신호 프로브 검출 단계는(b-2-i) 그 분리된 신호 프로브를, 그 신호 프로브의 결합 태그를 통해 그 결합 태그에 대한 결합 파트너가 코팅되어 있는 분석용 지지체에 처리하여 결합 태그와 결합 파트너의 특이적 결합을 통해 분석용 지지체에 고정시키는 단계와, (b-2-ii) 그 지지체에 고정된 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제28항에 있어서,상기 결합 태그는 그 결합 태그는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
- 제28항에 있어서,상기 결합 파트너는 스트렙타비딘 또는 스트렙타비딘 유사체인 것을 특징으로 하는검출방법.
- 제28항에 있어서,고정영역이 기지의 서열로 상기 신호발생영역에 인접하여 추가로 연결되어 있고,상기 (b-2-ii) 신호 프로브의 신호 검출 단계는상기 고정영역에 상보적인 단일가닥 핵산 서열을 가지고 그 서열에 상기 결합 파트너와 특이적으로 결합할 수 있는 결합 태그를 가진 고정핵산분자를 상기 지지체에 처리하는 단계, 및그 처리 단계 후 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제31항에 있어서,상기 고정핵산분자의 결합 태크는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
- (a) 분석대상 시료에 그 표적분자에 특이적으로 결합하는 신호 프로브와 그 신호 프로브가 특이적으로 결합하는 표적분자의 부위와 동일한 부위에 특이적으로 결합하는 영역과 그 영역에 자성입자가 연결된 포획 경쟁분자를 정량하여 처리하여 상기 포획 경쟁분자와 상기 신호 프로브 사이의 복합체를 형성시킴과 함께, 그 복합체를 포함하는 혼합물을 얻는 단계, 및(b) 그 혼합물 중의 복합체의 신호 프로브를 검출하는 단계를 포함하되,상기 신호 프로브는 (i) 표적단백질에 특이적으로 결합하는 영역과 (ii) 그 표적단백질과의 특이적 결합영역에 결합된 신호발생영역을 포함하고, 그 신호발생영역은 서로 상보적으로 가교결합된 이중가닥 핵산으로 그 이중가닥 핵산에는 동일한 신호발생물질로 표지되거나 서로 다른 신호발생물질로 표지된 2개 이상의 영역이 존재함으로써,상기 신호 프로브의 검출 단계는 상기 신호발생영역의 신호를 검출함에 의해 수행되고,상기 신호 리간드는 포획 경쟁분자와 표적분자 모두를 검출할 수 있는 양 이하로 처리되는분석대상 시료 중의 표적 단백질의 검출방법.
- 제33항에 있어서,상기 표적분자와의 특이적 결합영역은 단일가닥 핵산, 항체, 항원 또는 압타머인 것을 특징으로 하는검출방법.
- 제33항에 있어서,상기 (b) 신호 프로브 검출 단계는(b-1) 상기 혼합물 중의 복합체로부터 신호 프로브만을 분리시키는 단계, 및(b-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되는 것을 특징을 하는검출방법.
- 제33항에 있어서,상기 (b) 신호 프로브 검출 단계는(b-1) 상기 혼합물 중의 복합체로부터 신호 프로브만을 분리시키는 단계, 및(b-2) 그 분리된 신호 프로브를 검출하는 단계를 포함하여 수행되고,상기 (b-1) 신호 프로브만을 분리시키는 단계는(b-1-i) 상기 혼합물에 자석을 적용하여 상기 복합체와 복합체를 형성하지 않은 포획 경쟁분자만을 자석에 결합시켜 혼합물의 나머지 성분을 제거하는 단계,(b-1-ii) 자석에 결합되어 있는 복합체로부터 신호 프로브만을 분리시키는 단계를 포함하여 수행되되는 것을 특징으로 하는검출방법.
- 제36항에 있어서,상기 신호 프로브는 그 표적분자의 특이적 결합영역 반대쪽에 결합 태크가 연결되어 있고,상기 (b-2)의 신호 프로브 검출 단계는(b-2-i) 그 분리된 신호 프로브를, 그 신호 프로브의 결합 태그를 통해 그 결합 태그에 대한 결합 파트너가 코팅되어 있는 분석용 지지체에 처리하여 결합 태그와 결합 파트너의 특이적 결합을 통해 분석용 지지체에 고정시키는 단계와, (b-2-ii) 그 지지체에 고정된 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제37항에 있어서,상기 결합 태그는 그 결합 태그는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
- 제37항에 있어서,상기 결합 파트너는 스트렙타비딘 또는 스트렙타비딘 유사체인 것을 특징으로 하는검출방법.
- 제37항에 있어서,고정영역이 기지의 서열로 상기 신호발생영역에 인접하여 추가로 연결되어 있고,상기 (b-2-ii) 신호 프로브의 신호 검출 단계는상기 고정영역에 상보적인 단일가닥 핵산 서열을 가지고 그 서열에 상기 결합 파트너와 특이적으로 결합할 수 있는 결합 태그를 가진 고정핵산분자를 상기 지지체에 처리하는 단계, 및그 처리 단계 후 신호 프로브의 신호를 검출하는 단계를 포함하여 수행되는 것을 특징으로 하는검출방법.
- 제40항에 있어서,상기 고정핵산분자의 결합 태크는 비오틴 또는 비오틴 유사체인 것을 특징으로 하는검출방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3029178A CA3029178C (en) | 2016-06-30 | 2017-06-30 | Double-stranded nucleic acid signal probe and method for detecting target molecule using same |
EP17820585.2A EP3480320A4 (en) | 2016-06-30 | 2017-06-30 | BICATENARY NUCLEIC ACID SIGNAL PROBE AND TARGET MOLECULE DETECTION METHOD USING THE SAME |
CN201780040968.9A CN110312808A (zh) | 2016-06-30 | 2017-06-30 | 双链核酸信号探针以及利用上述双链核酸信号探针的靶分子检测方法 |
JP2018569145A JP6940532B2 (ja) | 2016-06-30 | 2017-06-30 | 二本鎖核酸信号プローブおよびこれを用いた標的分子の検出方法 |
US16/313,670 US20200308631A1 (en) | 2016-06-30 | 2017-06-30 | Double-stranded nucleic acid signal probe and method for detecting target molecule using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160082612 | 2016-06-30 | ||
KR10-2016-0082612 | 2016-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018004309A1 true WO2018004309A1 (ko) | 2018-01-04 |
Family
ID=60787015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/006987 WO2018004309A1 (ko) | 2016-06-30 | 2017-06-30 | 이중가닥 핵산 신호 프로브 및 이를 이용한 표적분자의 검출방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200308631A1 (ko) |
EP (1) | EP3480320A4 (ko) |
JP (1) | JP6940532B2 (ko) |
KR (1) | KR101913163B1 (ko) |
CN (1) | CN110312808A (ko) |
CA (1) | CA3029178C (ko) |
WO (1) | WO2018004309A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108444966A (zh) * | 2018-04-16 | 2018-08-24 | 成都博奥晶芯生物科技有限公司 | 一种激光微阵列芯片扫描仪的浓度梯度荧光校准片 |
CN111458506B (zh) * | 2020-03-08 | 2023-01-06 | 复旦大学 | 一种基于TdT信号放大的结直肠癌外泌体检测方法和体系 |
CN114544937B (zh) * | 2020-11-11 | 2023-04-07 | 艾克发(北京)生物技术有限公司 | 一种多重信号放大系统及其在免疫吸附间接法检测中的应用 |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019813A1 (en) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Nucleic acid ligands |
WO1992015673A1 (en) | 1991-03-11 | 1992-09-17 | The University Of Georgia Research Foundation, Inc. | Cloning and expression of renilla luciferase |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
US5665554A (en) | 1994-06-09 | 1997-09-09 | Amersham International Plc | Magnetic bead precipitation method |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
WO1998014605A1 (en) | 1996-10-04 | 1998-04-09 | Loma Linda University | Renilla luciferase and green fluorescent protein fusion genes |
US5741668A (en) | 1994-02-04 | 1998-04-21 | Rutgers, The State University Of New Jersey | Expression of a gene for a modified green-fluorescent protein |
WO1998026277A2 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
WO1999049019A2 (en) | 1998-03-27 | 1999-09-30 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
US6027945A (en) | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
WO2001014591A1 (en) * | 1999-08-21 | 2001-03-01 | Fox John S | High sensitivity biomolecule detection with magnetic particles |
JP2001136970A (ja) | 1999-11-12 | 2001-05-22 | Toyobo Co Ltd | 粒子担体を使用する改良された核酸の抽出方法 |
US20050233317A1 (en) * | 1999-10-08 | 2005-10-20 | National Institute of Advanced Industrial Science and Technology, a Japanese corporation | Modulate aptamer and method of detecting target protein by using the same |
KR100541282B1 (ko) | 2004-06-29 | 2006-01-10 | 경북대학교 산학협력단 | 초상자성 산화철계 나노입자를 이용한 간 조영제 및 그제조방법 |
KR20060061494A (ko) | 2004-12-02 | 2006-06-08 | 요업기술원 | 핵산(dna/rna) 분리정제용 기능성 실리카자성나노입자 및 그 제조방법 |
US7078224B1 (en) | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
US7183002B2 (en) | 2000-03-24 | 2007-02-27 | Qiagen, Gmbh | Porous ferro- or ferrimagnetic glass particles for isolating molecules |
KR20090088299A (ko) | 2008-02-14 | 2009-08-19 | (주)바이오니아 | 구형 실리카 자성입자 및 이의 제조방법 |
WO2010021516A2 (ko) * | 2008-08-21 | 2010-02-25 | 경북대학교 산학협력단 | 뇌 손상 치료를 위한 리포칼린 2의 신규한 용도 |
KR20100105605A (ko) * | 2007-11-21 | 2010-09-29 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 개선된 fret-프로브 및 이의 용도 |
US8519115B2 (en) | 2008-08-14 | 2013-08-27 | Nanostring Technologies, Inc. | Stable nanoreporters |
WO2014084545A1 (ko) * | 2012-11-28 | 2014-06-05 | 서울대학교산학협력단 | 미세 유체칩을 이용한 나노입자 분리 및 이를 이용한 생체물질분석방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19623895C2 (de) * | 1996-06-07 | 1999-05-06 | Hunke & Jochheim | Halter für Wendetafeln od. dgl. |
JP3262531B2 (ja) * | 1997-10-02 | 2002-03-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 曲げられたフライング・リード・ワイヤ・ボンデイング・プロセス |
CA2335324A1 (en) * | 1998-07-17 | 2000-01-27 | Genetag Technology, Inc. | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
EP2801624B1 (en) * | 2001-03-16 | 2019-03-06 | Singular Bio, Inc | Arrays and methods of use |
WO2008124847A2 (en) | 2007-04-10 | 2008-10-16 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
US8877438B2 (en) | 2010-07-20 | 2014-11-04 | California Institute Of Technology | Self-assembled polynucleotide structure |
EP2633080B1 (en) | 2010-10-29 | 2018-12-05 | President and Fellows of Harvard College | Method of detecting targets using fluorescently labelled nucleic acid nanotube probes |
KR20140068758A (ko) * | 2012-11-28 | 2014-06-09 | 서울대학교산학협력단 | 미세 유체칩을 이용한 나노입자 분리 및 이를 이용한 생체물질분석방법 |
EP3008201B1 (en) * | 2013-06-12 | 2019-08-07 | The General Hospital Corporation | Methods for multiplexed detection of target molecules and uses thereof |
-
2017
- 2017-06-30 EP EP17820585.2A patent/EP3480320A4/en not_active Withdrawn
- 2017-06-30 CN CN201780040968.9A patent/CN110312808A/zh active Pending
- 2017-06-30 US US16/313,670 patent/US20200308631A1/en not_active Abandoned
- 2017-06-30 JP JP2018569145A patent/JP6940532B2/ja active Active
- 2017-06-30 WO PCT/KR2017/006987 patent/WO2018004309A1/ko unknown
- 2017-06-30 CA CA3029178A patent/CA3029178C/en active Active
- 2017-06-30 KR KR1020170083788A patent/KR101913163B1/ko active IP Right Grant
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US5418155A (en) | 1989-12-29 | 1995-05-23 | University Of Georgia Research Foundation, Inc. | Isolated Renilla luciferase and method of use thereof |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
WO1991019813A1 (en) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Nucleic acid ligands |
US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
WO1992015673A1 (en) | 1991-03-11 | 1992-09-17 | The University Of Georgia Research Foundation, Inc. | Cloning and expression of renilla luciferase |
WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
US5741668A (en) | 1994-02-04 | 1998-04-21 | Rutgers, The State University Of New Jersey | Expression of a gene for a modified green-fluorescent protein |
US5665554A (en) | 1994-06-09 | 1997-09-09 | Amersham International Plc | Magnetic bead precipitation method |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
WO1998014605A1 (en) | 1996-10-04 | 1998-04-09 | Loma Linda University | Renilla luciferase and green fluorescent protein fusion genes |
WO1998026277A2 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
JP3253638B2 (ja) | 1997-01-21 | 2002-02-04 | プロメガ コーポレイション | シリカ磁気粒子を使用する生物学的目標物質の分離法 |
US6027945A (en) | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
US6673631B1 (en) | 1997-01-21 | 2004-01-06 | Promega Corporation | Simultaneous isolation and quantitation of DNA |
WO1999049019A2 (en) | 1998-03-27 | 1999-09-30 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
US7078224B1 (en) | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
WO2001014591A1 (en) * | 1999-08-21 | 2001-03-01 | Fox John S | High sensitivity biomolecule detection with magnetic particles |
US20050233317A1 (en) * | 1999-10-08 | 2005-10-20 | National Institute of Advanced Industrial Science and Technology, a Japanese corporation | Modulate aptamer and method of detecting target protein by using the same |
JP2001136970A (ja) | 1999-11-12 | 2001-05-22 | Toyobo Co Ltd | 粒子担体を使用する改良された核酸の抽出方法 |
US7183002B2 (en) | 2000-03-24 | 2007-02-27 | Qiagen, Gmbh | Porous ferro- or ferrimagnetic glass particles for isolating molecules |
KR100541282B1 (ko) | 2004-06-29 | 2006-01-10 | 경북대학교 산학협력단 | 초상자성 산화철계 나노입자를 이용한 간 조영제 및 그제조방법 |
KR20060061494A (ko) | 2004-12-02 | 2006-06-08 | 요업기술원 | 핵산(dna/rna) 분리정제용 기능성 실리카자성나노입자 및 그 제조방법 |
KR20100105605A (ko) * | 2007-11-21 | 2010-09-29 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 개선된 fret-프로브 및 이의 용도 |
KR20090088299A (ko) | 2008-02-14 | 2009-08-19 | (주)바이오니아 | 구형 실리카 자성입자 및 이의 제조방법 |
US8519115B2 (en) | 2008-08-14 | 2013-08-27 | Nanostring Technologies, Inc. | Stable nanoreporters |
WO2010021516A2 (ko) * | 2008-08-21 | 2010-02-25 | 경북대학교 산학협력단 | 뇌 손상 치료를 위한 리포칼린 2의 신규한 용도 |
WO2014084545A1 (ko) * | 2012-11-28 | 2014-06-05 | 서울대학교산학협력단 | 미세 유체칩을 이용한 나노입자 분리 및 이를 이용한 생체물질분석방법 |
Non-Patent Citations (12)
Title |
---|
A. ARABZADEH ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 237, 2002, pages 47 - 55 |
COTTEN ET AL., NUCL. ACID RES., vol. 19, 1991, pages 2629 - 2635 |
HOBBS ET AL., BIOCHEMISTRY, vol. 12, 1973, pages 5138 - 5145 |
METHODS ENZYMOL., vol. 267, 1996, pages 275 - 301 |
METHODS ENZYMOL., vol. 318, 2000, pages 193 - 214 |
METHODS MOL BIOL, vol. 498, 2009, pages 185 - 196 |
NAT. BIOTECHNOL., vol. 26, 2008, pages 317 - 325 |
NAT. BIOTECHNOL., vol. 26, no. 3, March 2008 (2008-03-01), pages 293 - 4 |
NUCLEIC ACIDS RES., vol. 15, no. 11, 11 June 1987 (1987-06-11), pages 4513 - 4534 |
RNA, vol. 20, no. 3, March 2014 (2014-03-01), pages 421 - 427 |
SCIENCE, vol. 249, no. 4968, 1990, pages 505 - 510 |
SPROAT ET AL., NUCL. ACID RES., vol. 19, 1991, pages 733 - 738 |
Also Published As
Publication number | Publication date |
---|---|
EP3480320A4 (en) | 2020-03-11 |
JP6940532B2 (ja) | 2021-09-29 |
KR101913163B1 (ko) | 2018-11-01 |
JP2019526231A (ja) | 2019-09-19 |
CA3029178C (en) | 2022-07-19 |
EP3480320A1 (en) | 2019-05-08 |
CN110312808A (zh) | 2019-10-08 |
KR20180003479A (ko) | 2018-01-09 |
US20200308631A1 (en) | 2020-10-01 |
CA3029178A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013032242A2 (ko) | 그래핀을 이용한 타겟 비고정화 방식의 앱타머 선별방법 및 이로부터 선별된 앱타머 | |
WO2018004309A1 (ko) | 이중가닥 핵산 신호 프로브 및 이를 이용한 표적분자의 검출방법 | |
JP6014091B2 (ja) | 検体中の測定対象成分の測定方法及び測定用キット | |
KR0171617B1 (ko) | 단백질-핵산 프로브 및 그를 사용하는 면역분석법 | |
WO2021006570A1 (ko) | 압타머의 선별 방법 및 압타머를 이용한 면역 분석 방법 | |
WO2017180911A1 (en) | Methods and systems for detecting or monitoring aggregation related to amyotrophic lateral sclerosis | |
EP2210098A1 (en) | Methods and compositions for detection and enrichment of target small rnas | |
KR100252688B1 (ko) | 면역검정법에사용하기위한간섭억제제 | |
WO2015170844A1 (ko) | 마그네틱(magnetic)을 이용한 형광다중면역검사 | |
WO2015034250A1 (ko) | 카드뮴에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
CN112708660B (zh) | Crispr-poct检测组合物及其应用 | |
Choi et al. | Detecting early-stage malignant melanoma using a calcium switch-enriched exosome subpopulation containing tumor markers as a sample | |
JP7209498B2 (ja) | B型肝炎ウイルスコア抗体の免疫測定方法 | |
Jiang et al. | Bio-SCAN V2: A CRISPR/dCas9-based lateral flow assay for rapid detection of theophylline | |
WO2021112464A1 (ko) | 엑소좀 액체생검 샘플 제조장치, 제조방법 및 이로부터 제조된 엑소좀 액체생검 샘플 분석방법 | |
NL2034227B1 (en) | Method for efficiently enriching chromatin open region binding proteins and application thereof | |
Brasino et al. | Real-time femtomolar detection of cancer biomarkers from photoconjugated antibody–phage constructs | |
KR101911859B1 (ko) | 이중가닥 핵산 신호 프로브 및 이를 이용한 표적분자의 검출방법 | |
WO2021112559A1 (ko) | 시료의 표적분자 집단에 대한 프로파일을 얻는 방법 | |
WO2019112178A1 (ko) | 오담에 특이적으로 결합하는 dna 앱타머 및 그의 용도 | |
EP3978510A1 (en) | Norovirus-binding peptide | |
JPH05505526A (ja) | 多発光団蛍光プローブ | |
WO2021060897A1 (ko) | 새로운 외상성 뇌손상 및 감염병 poct 진단시스템 | |
EP3995506A1 (en) | Norovirus-binding peptide | |
WO2023191543A1 (ko) | 암의 진단용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17820585 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3029178 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018569145 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017820585 Country of ref document: EP Effective date: 20190130 |